SG10201912817YA - Tissue factor pathway inhibitor antibodies and uses thereof - Google Patents

Tissue factor pathway inhibitor antibodies and uses thereof

Info

Publication number: SG10201912817YA
Authority: SG; Singapore
Prior art keywords: tissue factor; pathway inhibitor; factor pathway; inhibitor antibodies; antibodies
Prior art date: 2015-08-19

Application number

SG10201912817YA

Other languages

English (en)

Inventor

James R Apgar

Susan Benard

Gregory J Carven

Sunita R Hett

Matthew Holsti

Reema Jasuja

Macy Jin

Zong Sean Juo

Debra Pittman

Mark Stahl

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-19

Filing date

2016-08-10

Publication date

2020-02-27

2016-08-10 Application filed by Pfizer filed Critical Pfizer

2020-02-27 Publication of SG10201912817YA publication Critical patent/SG10201912817YA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG10201912817YA 2015-08-19 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof SG10201912817YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562207229P	2015-08-19	2015-08-19
US201662360205P	2016-07-08	2016-07-08

Publications (1)

Publication Number	Publication Date
SG10201912817YA true SG10201912817YA (en)	2020-02-27

Family

ID=56894019

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201912817YA SG10201912817YA (en)	2015-08-19	2016-08-10	Tissue factor pathway inhibitor antibodies and uses thereof

Country Status (20)

Country	Link
US (5)	US10550200B2 (ru)
EP (1)	EP3337827A2 (ru)
JP (4)	JP6664467B2 (ru)
KR (4)	KR102536303B1 (ru)
CN (2)	CN107922506B (ru)
AU (2)	AU2016307967C9 (ru)
CA (2)	CA2939010C (ru)
CO (1)	CO2018001473A2 (ru)
IL (3)	IL302353A (ru)
MX (2)	MX391935B (ru)
MY (1)	MY195443A (ru)
NZ (1)	NZ739871A (ru)
PE (2)	PE20240142A1 (ru)
PH (1)	PH12018500211A1 (ru)
RU (1)	RU2705540C2 (ru)
SA (1)	SA518390944B1 (ru)
SG (1)	SG10201912817YA (ru)
TW (1)	TWI640538B (ru)
WO (1)	WO2017029583A2 (ru)
ZA (1)	ZA201800453B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2379600E (pt) †	2008-12-22	2014-04-29	Novo Nordisk As	Anticorpos contra inibidor da via de fator tecidual
DK3345615T3 (da)	2010-03-01	2020-01-20	Bayer Healthcare Llc	Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
SG10201912817YA (en)	2015-08-19	2020-02-27	Pfizer	Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (ko) *	2018-09-21	2021-12-13	주식회사 녹십자	고효율 항-tfpi 항체 조성물
US20210395391A1 (en) *	2018-10-11	2021-12-23	Pfizer Inc.	Dosage Regimen for TFPI Antagonists
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体
KR20220079561A (ko) *	2019-09-16	2022-06-13	옵시디오, 엘엘씨	항-줄기세포 인자 항체 및 이의 사용 방법
CN114786717B (zh) *	2019-11-13	2024-12-17	辉瑞公司	稳定的水性抗-tfpi抗体制剂
KR102140653B1 (ko)	2020-01-13	2020-08-03	이선재	떡 연속증숙장치
US20230340089A1 (en) *	2020-05-14	2023-10-26	City Of Hope	Smc1a antibodies and uses thereof
CN116472288A (zh) *	2020-11-06	2023-07-21	诺华股份有限公司	抗体Fc变体
CN113325185B (zh) *	2021-07-09	2024-04-19	重庆鼎润医疗器械有限责任公司	多水平质控品及其制备方法和在血栓弹力图检测上的应用
US20250066436A1 (en)	2021-12-22	2025-02-27	Royal College Of Surgeons In Ireland	A conjugate for use in localising a molecule to the vascular endothelium
CN117285632A (zh) *	2022-06-17	2023-12-26	安源医药科技（上海）有限公司	针对tfpi的单克隆抗体及其用途
CN116903739B (zh) *	2023-03-28	2023-12-15	中国人民解放军军事科学院军事医学研究院	一种抗s100b蛋白的抗体及其应用
WO2025124481A1 (zh) *	2023-12-13	2025-06-19	苏州康宁杰瑞生物科技有限公司	Tfpi抗体用于治疗血友病

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4754065A (en)	1984-12-18	1988-06-28	Cetus Corporation	Precursor to nucleic acid probe
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en)	1988-05-30	1995-06-06	Depotech Corporation	Heterovesicular liposomes
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
EP0832980B1 (en)	1989-01-23	2002-06-19	Chiron Corporation	Recombinant therapies for infection and hyperproliferative disorders
DE69034168T3 (de)	1989-03-21	2013-04-11	Vical, Inc.	Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP1645635A3 (en)	1989-08-18	2010-07-07	Oxford Biomedica (UK) Limited	Replication defective recombinant retroviruses expressing a palliative
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
ZA911974B (en)	1990-03-21	1994-08-22	Res Dev Foundation	Heterovesicular liposomes
DK0648271T3 (da)	1991-08-20	2003-07-21	Us Gov Health & Human Serv	Adenovirusmedieret overførsel af gener til mave-/tarmkanal
WO1993010218A1 (en)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vectors including foreign genes and negative selective markers
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
FR2688514A1 (fr)	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993025234A1 (en)	1992-06-08	1993-12-23	The Regents Of The University Of California	Methods and compositions for targeting specific tissue
CA2137361A1 (en)	1992-06-10	1993-12-23	W. French Anderson	Vector particles resistant to inactivation by human serum
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
CA2145641C (en)	1992-12-03	2008-05-27	Richard J. Gregory	Pseudo-adenovirus vectors
DK0695169T3 (da)	1993-04-22	2003-03-17	Skyepharma Inc	Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
JP3532566B2 (ja)	1993-06-24	2004-05-31	エル．グラハム，フランク	遺伝子治療のためのアデノウイルスベクター
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
EP0716148B1 (en)	1993-09-15	2004-01-02	Chiron Corporation	Recombinant alphavirus vectors
CN1263864C (zh)	1993-10-25	2006-07-12	坎吉公司	重组腺病毒载体及其使用方法
WO1995013796A1 (en)	1993-11-16	1995-05-26	Depotech Corporation	Vesicles with controlled release of actives
US6436908B1 (en)	1995-05-30	2002-08-20	Duke University	Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ATE381624T1 (de)	1994-05-09	2008-01-15	Oxford Biomedica Ltd	Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en)	1994-11-30	1996-06-19	Chiron Viagene, Inc.	Recombinant alphavirus vectors
DE69739286D1 (de)	1996-05-06	2009-04-16	Oxford Biomedica Ltd	Rekombinationsunfähige retrovirale vektoren
WO1999018792A1 (en)	1997-10-10	1999-04-22	Johns Hopkins University	Gene delivery compositions and methods
JP4340339B2 (ja) *	1998-07-31	2009-10-07	財団法人化学及血清療法研究所	血液凝固因子もしくは血液凝固制御因子欠損モデル動物並びに該モデル動物の作製方法
US7771951B2 (en)	2001-12-03	2010-08-10	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
CA2921578C (en)	2002-12-24	2017-02-14	Rinat Neuroscience Corp.	Anti-ngf antibodies and methods using same
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
JP2010536363A (ja) *	2007-08-23	2010-12-02	エルエフビーバイオテクノロジース	ファクターｖｉｉｉのｃ１ドメインに対する阻害抗体の阻害活性を中性化する抗イデオタイプ抗体
FR2933908B1 (fr)	2008-07-16	2010-12-24	Renault Sas	Dispositif de protection pour une porte de vehicule automobile.
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010071894A2 (en) *	2008-12-19	2010-06-24	Baxter International Inc.	Tfpi inhibitors and methods of use
JP5791512B2 (ja)	2008-12-22	2015-10-07	ノヴォノルディスクアー／エス	組織因子経路阻害因子（ｔｆｐｉ）に対する抗体
PT2379600E (pt) *	2008-12-22	2014-04-29	Novo Nordisk As	Anticorpos contra inibidor da via de fator tecidual
EP3216462A3 (en)	2010-02-26	2017-12-20	Novo Nordisk A/S	Stable antibody containing compositions
DK3345615T3 (da)	2010-03-01	2020-01-20	Bayer Healthcare Llc	Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
CN105566490A (zh) *	2010-03-19	2016-05-11	巴克斯特国际公司	Tfpi抑制剂及使用方法
KR20130086144A (ko)	2010-05-28	2013-07-31	노보 노르디스크 에이/에스	항체 및 보존제를 포함하는 안정한 다중-투여 조성물
EP2588499B1 (en) *	2010-06-30	2020-04-08	Novo Nordisk A/S	Antibodies that are capable of specifically binding tissue factor pathway inhibitor
MX2013011218A (es) *	2011-04-01	2013-10-17	Bayer Healthcare Llc	Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
CN103890246A (zh)	2011-08-18	2014-06-25	亲和生物科学公司	可溶性多肽
BR112014024373A2 (pt)	2012-03-30	2017-08-08	Bayer Healthcare Llc	anticorpos regulados por protease
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
ES2926773T3 (es)	2013-03-15	2022-10-28	Novo Nordisk As	Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
CN105452298B (zh)	2013-03-15	2021-08-31	拜尔健康护理有限责任公司	改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
HK1215262A1 (zh)	2013-03-15	2016-08-19	Bayer Healthcare Llc	針對組織因子途徑抑制劑的前體藥物抗體
JP6584397B2 (ja)	2013-07-19	2019-10-02	ノヴォノルディスクアー／エス	凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
US20170322218A1 (en)	2014-11-27	2017-11-09	Public University Corporation Yokohama City University	Method and reagent for detecting ovarian clear cell adenocarcinoma
EA036490B1 (ru)	2015-02-25	2020-11-17	Могам Инститьют Фор Байомедикал Рисерч	Антитела, связывающиеся с tfpi, и содержащая их композиция
SG10201912817YA (en) *	2015-08-19	2020-02-27	Pfizer	Tissue factor pathway inhibitor antibodies and uses thereof
US20210395391A1 (en)	2018-10-11	2021-12-23	Pfizer Inc.	Dosage Regimen for TFPI Antagonists

2016
- 2016-08-10 SG SG10201912817YA patent/SG10201912817YA/en unknown
- 2016-08-10 JP JP2018508228A patent/JP6664467B2/ja active Active
- 2016-08-10 MX MX2018002048A patent/MX391935B/es unknown
- 2016-08-10 IL IL302353A patent/IL302353A/en unknown
- 2016-08-10 KR KR1020227029694A patent/KR102536303B1/ko active Active
- 2016-08-10 KR KR1020187007333A patent/KR102068915B1/ko active Active
- 2016-08-10 PE PE2023001019A patent/PE20240142A1/es unknown
- 2016-08-10 IL IL289766A patent/IL289766B2/en unknown
- 2016-08-10 EP EP16763319.7A patent/EP3337827A2/en active Pending
- 2016-08-10 MY MYPI2018700189A patent/MY195443A/en unknown
- 2016-08-10 CN CN201680048417.2A patent/CN107922506B/zh active Active
- 2016-08-10 CN CN202111341215.6A patent/CN114163531B/zh active Active
- 2016-08-10 RU RU2018104283A patent/RU2705540C2/ru active
- 2016-08-10 NZ NZ739871A patent/NZ739871A/en unknown
- 2016-08-10 KR KR1020237017125A patent/KR20230074843A/ko not_active Ceased
- 2016-08-10 PE PE2018000267A patent/PE20180556A1/es unknown
- 2016-08-10 AU AU2016307967A patent/AU2016307967C9/en active Active
- 2016-08-10 KR KR1020197023699A patent/KR102438650B1/ko active Active
- 2016-08-10 WO PCT/IB2016/054814 patent/WO2017029583A2/en not_active Ceased
- 2016-08-16 TW TW105126115A patent/TWI640538B/zh active
- 2016-08-16 CA CA2939010A patent/CA2939010C/en active Active
- 2016-08-16 CA CA3174958A patent/CA3174958C/en active Active
- 2016-08-17 US US15/239,556 patent/US10550200B2/en active Active
2018
- 2018-01-14 IL IL256913A patent/IL256913B/en unknown
- 2018-01-22 ZA ZA2018/00453A patent/ZA201800453B/en unknown
- 2018-01-26 PH PH12018500211A patent/PH12018500211A1/en unknown
- 2018-02-14 CO CONC2018/0001473A patent/CO2018001473A2/es unknown
- 2018-02-16 MX MX2022004834A patent/MX2022004834A/es unknown
- 2018-02-18 SA SA518390944A patent/SA518390944B1/ar unknown
2019
- 2019-12-17 US US16/716,790 patent/US10875929B2/en active Active
2020
- 2020-02-18 JP JP2020024908A patent/JP7303761B2/ja active Active
- 2020-11-24 US US17/102,883 patent/US11634504B2/en active Active
2022
- 2022-02-18 AU AU2022201091A patent/AU2022201091B2/en active Active
- 2022-02-24 JP JP2022026738A patent/JP2022084623A/ja active Pending
2023
- 2023-03-13 US US18/182,619 patent/US12168698B2/en active Active
2024
- 2024-02-08 JP JP2024017935A patent/JP2024054266A/ja active Pending
- 2024-11-05 US US18/937,384 patent/US20250145732A1/en active Pending

Also Published As

Publication number	Publication date
KR20230074843A (ko)	2023-05-31
WO2017029583A3 (en)	2017-07-20
JP6664467B2 (ja)	2020-03-13
WO2017029583A2 (en)	2017-02-23
KR20190097319A (ko)	2019-08-20
MY195443A (en)	2023-01-21
NZ739871A (en)	2022-05-27
JP7303761B2 (ja)	2023-07-05
JP2020096627A (ja)	2020-06-25
CA3174958A1 (en)	2017-02-19
US20230416405A1 (en)	2023-12-28
PE20180556A1 (es)	2018-04-02
KR102068915B9 (ko)	2023-10-12
CA2939010A1 (en)	2017-02-19
PE20240142A1 (es)	2024-02-01
RU2705540C2 (ru)	2019-11-07
MX2022004834A (es)	2022-05-16
NZ756365A (en)	2025-02-28
JP2022084623A (ja)	2022-06-07
PH12018500211A1 (en)	2018-08-13
KR20220136381A (ko)	2022-10-07
US12168698B2 (en)	2024-12-17
US20250145732A1 (en)	2025-05-08
IL302353A (en)	2023-06-01
US20210101998A1 (en)	2021-04-08
CN114163531B (zh)	2025-06-13
US10875929B2 (en)	2020-12-29
AU2016307967C9 (en)	2025-02-20
US20170073428A1 (en)	2017-03-16
CN107922506A (zh)	2018-04-17
KR102438650B1 (ko)	2022-08-31
BR112018001478A2 (pt)	2018-09-18
AU2016307967A1 (en)	2018-02-01
AU2016307967C1 (en)	2023-10-05
AU2022201091B2 (en)	2025-03-20
AU2022201091A1 (en)	2022-03-10
IL256913B (en)	2022-02-01
US20200190214A1 (en)	2020-06-18
AU2016307967B2 (en)	2022-02-17
ZA201800453B (en)	2018-12-19
KR102536303B1 (ko)	2023-05-26
MX2018002048A (es)	2018-04-13
CN107922506B (zh)	2021-11-09
JP2024054266A (ja)	2024-04-16
EP3337827A2 (en)	2018-06-27
IL289766A (en)	2022-03-01
CA3174958C (en)	2025-05-27
CA2939010C (en)	2025-09-16
CO2018001473A2 (es)	2018-05-10
IL256913A (en)	2018-03-29
IL289766B2 (en)	2023-10-01
SA518390944B1 (ar)	2022-02-08
KR20180030936A (ko)	2018-03-26
MX391935B (es)	2025-03-21
RU2018104283A3 (ru)	2019-09-19
US10550200B2 (en)	2020-02-04
TW201718659A (zh)	2017-06-01
JP2018527922A (ja)	2018-09-27
US11634504B2 (en)	2023-04-25
TWI640538B (zh)	2018-11-11
CN114163531A (zh)	2022-03-11
IL289766B1 (en)	2023-06-01
KR102068915B1 (ko)	2020-01-22
RU2018104283A (ru)	2019-09-19

Publication	Publication Date	Title
IL289766A (en)	2022-03-01	tfpi inhibitory antibodies and their uses
HUS2500022I1 (hu)	2025-06-28	Terápiás ellenanyagok és alkalmazásaik
IL285375B2 (en)	2025-11-01	IL-8-binding antibodies and their uses
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
IL258970A (en)	2018-06-28	Bivalent bromodomain inhibitors and their uses
IL258284A (en)	2018-05-31	Anti-Lag 3 antibodies and their uses
IL257263A (en)	2018-03-29	Antibodies against angptl8 and their use
IL254954A0 (en)	2017-12-31	Anti-pacap antibodies and their uses
GB201605126D0 (en)	2016-05-11	Inhibitors and their uses
SG11201708624YA (en)	2017-11-29	Therapeutic antibodies and uses thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL254916B (en)	2021-10-31	Inhibitors and their uses
IL255530A (en)	2018-01-31	Efflux-pump inhibitors and therapeutic uses thereof
HK40065949B (zh)	2025-08-29	组织因子途径抑制剂抗体及其用途
GB2545167B (en)	2022-02-16	Cloches and use thereof
GB201505975D0 (en)	2015-05-20	Inhibitors and their uses
GB201505971D0 (en)	2015-05-20	Inhibitors and their uses
GB201514770D0 (en)	2015-09-30	Compounds and their use